Jessica Fye
Stock Analyst at JP Morgan
(4.00)
# 637
Out of 4,761 analysts
178
Total ratings
57.02%
Success rate
9.34%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Overweight | $167 → $168 | $154.58 | +8.68% | 9 | Feb 13, 2025 | |
| INSM Insmed | Maintains: Overweight | $83 → $92 | $83.61 | +10.03% | 7 | Feb 7, 2025 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $28 → $24 | $21.59 | +11.16% | 5 | Jan 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $503 → $500 | $480.33 | +4.10% | 7 | Dec 23, 2024 | |
| MRNA Moderna | Maintains: Underweight | $59 → $45 | $33.73 | +33.41% | 11 | Nov 26, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $124 → $122 | $117.88 | +3.50% | 10 | Nov 26, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $81 → $89 | $128.54 | -30.76% | 7 | Nov 4, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $110 → $109 | $68.73 | +58.59% | 3 | Oct 30, 2024 | |
| INCY Incyte | Maintains: Neutral | $65 → $71 | $71.38 | -0.53% | 5 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Neutral | $32 → $26 | $35.50 | -26.76% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.83 | +153.59% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $57 | $57.44 | -0.77% | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $55 | $32.69 | +68.25% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $248 → $280 | $251.00 | +11.55% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $202 | $136.65 | +47.82% | 3 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $66 | $29.87 | +120.96% | 4 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $36.86 | +46.50% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $53.16 | -26.64% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $300 | $367.36 | -18.34% | 14 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $8.74 | +48.74% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $21.65 | -21.48% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.96 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $7.84 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.85 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.59 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $10 | $9.39 | +6.50% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $38.92 | +95.27% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $204 → $240 | $5.12 | +4,587.50% | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.84 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $0.94 | +2,252.94% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.73 | +864.19% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $13.07 | +106.58% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.53 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.92 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $5.17 | - | 4 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.38 | - | 1 | Feb 8, 2018 |
Ascendis Pharma
Feb 13, 2025
Maintains: Overweight
Price Target: $167 → $168
Current: $154.58
Upside: +8.68%
Insmed
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $83.61
Upside: +10.03%
Denali Therapeutics
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $21.59
Upside: +11.16%
Vertex Pharmaceuticals
Dec 23, 2024
Maintains: Overweight
Price Target: $503 → $500
Current: $480.33
Upside: +4.10%
Moderna
Nov 26, 2024
Maintains: Underweight
Price Target: $59 → $45
Current: $33.73
Upside: +33.41%
BioNTech SE
Nov 26, 2024
Maintains: Neutral
Price Target: $124 → $122
Current: $117.88
Upside: +3.50%
Intra-Cellular Therapies
Nov 4, 2024
Maintains: Overweight
Price Target: $81 → $89
Current: $128.54
Upside: -30.76%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $68.73
Upside: +58.59%
Incyte
Oct 30, 2024
Maintains: Neutral
Price Target: $65 → $71
Current: $71.38
Upside: -0.53%
Alkermes
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $35.50
Upside: -26.76%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $11.83
Upside: +153.59%
Sep 19, 2024
Downgrades: Neutral
Price Target: $52 → $57
Current: $57.44
Upside: -0.77%
Aug 26, 2024
Maintains: Neutral
Price Target: $50 → $55
Current: $32.69
Upside: +68.25%
Aug 26, 2024
Maintains: Neutral
Price Target: $248 → $280
Current: $251.00
Upside: +11.55%
Aug 19, 2024
Maintains: Overweight
Price Target: $190 → $202
Current: $136.65
Upside: +47.82%
Jul 10, 2024
Maintains: Overweight
Price Target: $70 → $66
Current: $29.87
Upside: +120.96%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $36.86
Upside: +46.50%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $53.16
Upside: -26.64%
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $367.36
Upside: -18.34%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $8.74
Upside: +48.74%
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $21.65
Upside: -21.48%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.96
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $7.84
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.85
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.59
Upside: -
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $9.39
Upside: +6.50%
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $38.92
Upside: +95.27%
Mar 8, 2022
Upgrades: Overweight
Price Target: $204 → $240
Current: $5.12
Upside: +4,587.50%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $2.84
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $0.94
Upside: +2,252.94%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.73
Upside: +864.19%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $13.07
Upside: +106.58%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.53
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.92
Upside: -
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $5.17
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $8.38
Upside: -